Abstract
Thrombopoietin receptor (TPO-R) agonists have been shown to be effective in refractory chronic immune thrombocytopenia (ITP); however, their efficacy in patients under critical care is not known. We report the case of a female patient with a newly diagnosed ITP who experienced severe bleeding from an external wound. The patient was administered the standard treatments for ITP, which are high-dose intravenous immunoglobulin (IVIg) and corticosteroids. However, following failure of these treatments, we administered romiplostim on day 6 after the onset of ITP. On day 6 after the initiation of romiplostim, there was improvement in platelet count and bleeding tendency. We were subsequently able to perform a splenectomy successfully. The efficacy of TPO-R agonists in ITP has been reported in several situations, including before surgery in an ITP patient; however, the use of TPO-R for arterial bleeding with shock has not been reported. To our knowledge, the present article is a rare case report of the use of a TPO-R agonist in a patient with critical artery injury. Our data suggest that the early use of romiplostim is effective in emergency cases of newly diagnosed ITP with life-threatening bleeding, which is refractory to standard treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672–81.
Imbach P, Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med. 2011;365:734–41.
Godeau B, Chevret S, Varet B, Lefrère F, Zini JM, Bassompierre F, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomized, multicentre trial. Lancet. 2002;359:23–9.
Fujimura K, Miyakawa Y, Kurata Y, Kuwana M, Tomiyama Y. Murata M [Reference guide for management of adult idiopathic thrombocytopenic purpura (ITP) 2012 version]. Rinsho Ketsueki. 2012;53:433–42.
Shirasugi Y, Ando K, Hashino S, Nagasawa T, Kurata Y, Kishimoto Y, et al. A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura. Int J Hematol. 2009;90:157–65.
George JN, El-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1994;331:1207–11.
Wei Y, Ji XW, Wang YW, Wang JX, Yang EQ, Wang ZC, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a retrospective multicenter randomized trial. Blood. 2016;127:296–302.
Emilia G, Longo G, Luppi M, Gandini G, Morselli M, Ferrara L, et al. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood. 2001;97:812–4.
Fujimura K, Kuwana M, Kurata Y, Imamura M, Harada H, Sakamaki H, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol. 2005;81:162–8.
Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther. 2004;76:628–38.
Okazuka K, Masuko M, Matsuo Y, Miyakoshi S, Tanaka T, Kozakai T, et al. Successful treatment of severe newly diagnosed immune thrombocytopenia involving an alveolar hemorrhage with combination therapy consisting of romiplostim rituximab and vincristine. Intern Med. 2013;52:1239–42.
Contis A, Lazaro E, Greib C, Pellegrin JL, Viallard JF. Romiplostim as early treatment for refractory primary immune thrombocytopenia. Int J Hematol. 2013;98:520–4.
Kuter DJ. The biology of thrombopoietin and thrombopoietin receptor agonists. Int J Hematol. 2013;98:10–23.
Ruggeri M. Thrombopoietin receptor agonists in the treatment of immune thrombocytopenia: a clinician’s perspective. Am J Hematol. 2012;87:946–7.
Gómez-Almaguer D, Herrera-Rojas MA, Jaime-Pérez JC, Gómez-De-León A, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, et al. Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood. 2014;123:3906–8.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Watanabe, R., Tabayashi, T., Tomikawa, T. et al. Successful early romiplostim use in a case of severe immune thrombocytopenia with critical carotid arterial injury. Int J Hematol 105, 100–103 (2017). https://doi.org/10.1007/s12185-016-2094-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-016-2094-z